

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>KWON YOUNG</b> <hr/> (Last) (First) (Middle) <b>C/O MOMENTA PHARMACEUTICALS, INC.</b> <b>301 BINNEY STREET</b> <hr/> (Street) <b>CAMBRIDGE MA 02142</b> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>MOMENTA PHARMACEUTICALS INC</b> <b>[ MNTA ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) <b>X SVP, Chief Business Officer</b>
	3. Date of Earliest Transaction (Month/Day/Year) <b>08/07/2019</b>	
4. If Amendment, Date of Original Filed (Month/Day/Year) <b>08/09/2019</b>		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/08/2019		s <sup>(1)</sup>		636 <sup>(2)</sup>	D	\$11.67 <sup>(3)</sup>	101,352 <sup>(4)</sup>	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- The original Form 4 filed on August 9, 2019 is amended by this Form 4/A to correctly reflect the reporting person's share disposal of 636, not 626 shares of common stock.
- The original Form 4 filed on August 9, 2019 is amended by this Form 4/A to correctly reflect the reporting person's selling price of \$11.67 per share, not \$11.82 per share.
- The original Form 4 filed on August 9, 2019 is amended by this Form 4/A to correctly reflect the reporting person's ownership balance of 101,352, not 101,362 shares of common stock.

/s/ R. Mark Chamberlin as 08/13/2019  
attorney in fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**